Published: 2 December 2021
Publications
Recent approvals: new active ingredients or new indications
Published: 2 December 2021
Prescriber Update 42(4): 53–54
December 2021
For the period 16 July 2021 to 15 October 2021.
Recent approvals of medicines with new active ingredients
| Trade name (active ingredient) | Dose form and strength(s) | Therapeutic area |
|---|---|---|
| Xofluza (baloxavir marboxil) | Film-coated tablet 20 mg 40 mg |
Influenza |
| Calquence (acalabrutinib) | Capsule 100 mg |
Mantle cell lymphoma Chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) |
| Piqray (alpelisib) | Film-coated tablet 200 mg 250 mg (200 mg + 50 mg) 300 mg (150 mg +150 mg) |
Hormone receptor positive, HER2-negative, advanced or metastatic breast cancer with a PIK3CA mutation |
| Trumenba (Neisseria meningitidis group B factor H binding protein subfamily A + subfamily B) | Suspension for injection 120 mcg/0.5 mL |
Meningococcal B disease |
| Trulicity (dulaglutide) | Solution for injection 3 mg/mL |
Type 2 diabetes mellitus |
Approved medicines with new indications
| Trade Name (active ingredient) | Dose form and strength(s) | New therapeutic area(s) |
|---|---|---|
| Rinvoq (upadacitinib hemihydrate) | Modified release tablet 15 mg |
Atopic dermatitis |
| Vicks Vaporub (eucalyptus oil; menthol) | Topical ointment 1.33%; 2.82% |
Headache |
| Keytruda (pembrolizumab) | Concentrate for infusion 25 mg/mL |
Oesophageal cancer |
See the Medsafe website for:
